RISEUPTOHIV
RISEUPTOHIV
EDUCATION • RESOURCES • ADVOCACY
About Contact
ES HT
Quick Answer

Is there a once-a-day pill for HIV?

Answered in plain language, anchored to CDC, HIV.gov, and NIH.

Educational information only — not medical advice. Talk to your healthcare provider about your specific situation.
← Home
Share Facebook X WhatsApp Text Email LinkedIn Reddit Threads Bluesky

Yes. For most people starting HIV treatment today, treatment is one pill, once a day. The HHS/NIH adult and adolescent antiretroviral guidelines — updated May 27, 2026 — rate Biktarvy and Dovato as recommended initial regimens for most people (evidence rating AI), alongside dolutegravir plus two NRTIs. More than ten complete single-tablet regimens are FDA-approved, and the newest, Idvynso, arrived in April 2026.

What the 2026 guidelines actually recommend

The federal Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV carry an update date of May 27, 2026[2]. Their table of Recommended Initial Regimens for Most People With HIV — for people without a history of using long-acting cabotegravir as PrEP — lists three options, all rated AI (the strongest recommendation, from randomized trial data):

Dovato has limits worth knowing before you ask about it: it is not recommended for people with an HIV viral load above 500,000 copies/mL, for people who also have hepatitis B, or when treatment needs to start before resistance and hepatitis B results are back[1]. Other coformulated single tablets named in the guidelines' initial-regimen tables include Symtuza (darunavir/cobicistat/emtricitabine/TAF), Triumeq (rated BI, only for people who test HLA-B*5701-negative), Delstrigo (doravirine/TDF/lamivudine, BI, for people avoiding an integrase inhibitor or protease inhibitor), and Odefsey (rilpivirine/TAF/emtricitabine, BII, only when the viral load is under 100,000 copies/mL and CD4 is above 200)[1].

The single-tablet regimens available today

NIH's patient-facing drug list gives the approval history for each complete once-daily tablet [4]:

New in 2026: FDA approved Idvynso (doravirine/islatravir) on April 20, 2026 as a complete once-daily regimen — specifically to replace a current regimen in adults who are already virologically suppressed (HIV-1 RNA under 50 copies/mL) on a stable regimen, with no history of treatment failure and no known doravirine-resistance substitutions[5]. Genvoya, Stribild, Complera, Juluca, and Idvynso do not appear in the guidelines' initial-regimen tables — think of them as regimens people may already be doing well on, or may switch to, rather than starting points[1][5].

Why one pill a day matters — and why it isn't automatic

The guidelines are direct about the connection to adherence: “Once-daily regimens, including those with low pill burden … no food requirement, and few side effects or toxicities, are associated with higher levels of adherence”[3]. They also say something more honest than most marketing does: single-tablet regimens are “generally recommended when clinically appropriate, but high-quality evidence to definitively recommend them is lacking and shared decision-making between clinicians and people with HIV is essential (BIII)”[3].

The line worth carrying into your next appointment: “The only regimen that will work is the one that people can obtain and are willing and able to take”[3]. Two pills that you can afford and actually take beat one pill that your insurance fights you over every month. If pill count, side effects, cost, or privacy is the problem, that is a regimen conversation, not a personal failing.

Food rules and other differences between the pills

Not all once-daily tablets behave the same way. Biktarvy and Dovato can be taken with or without food[6]. Odefsey must be taken with a meal and cannot be combined with a proton pump inhibitor; Symtuza is also taken with food[1].

The backbone matters too: TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels — and safety, cost, and access all legitimately factor into the choice[1]. Regimens built on dolutegravir, bictegravir, or boosted darunavir carry the highest genetic barriers to resistance, which is why they are often chosen for people who have had a hard time taking pills on schedule[3].

Florida: what ADAP covers, and the 2026 formulary whiplash

The Florida ADAP formulary dated July 2026 covers Biktarvy, Dovato, Symtuza, Triumeq, Odefsey, Delstrigo, and Juluca — plus the injectables Cabenuva and Sunlenca — noting that unless otherwise marked, all brands, strengths, and dosage forms may be ordered pending wholesaler availability[7].

2026 was a rough year for access, and if your refill was disrupted you were not imagining it. After the state identified a projected $120 million shortfall, Biktarvy was removed from the formulary available to insured clients effective March 1, 2026 and Descovy access was limited — without the Department of Health's own HIV Section Medication Formulary Workgroup being consulted. The income eligibility ceiling was also cut from $62,600 a year to $20,748 before the Legislature directed DOH to restore the higher level and appropriated $31 million to ADAP through HB 697[9]. Florida DOH states that Biktarvy was restored to the ADAP formulary on July 1, 2026, along with Descovy, for clients in direct-dispense medication assistance and in the CVS Caremark retail program for copay and deductible help[8].

Florida ADAP eligibility: a positive HIV status, need for HIV medications, income at 0–400% of the federal poverty level, being uninsured or without adequate prescription coverage, and not being confined to a hospital, nursing home, hospice, or correctional facility. The ADAP Help Desk is 844-381-2327, and direct medication services run through Prime Therapeutics at 833-604-0925[8].

Related questions

What is the most commonly recommended once-a-day HIV pill?

The HHS/NIH guidelines updated May 27, 2026 rate Biktarvy (bictegravir/TAF/emtricitabine) and Dovato (dolutegravir/lamivudine) as recommended initial regimens for most people starting treatment, both with an AI evidence rating. Which one fits you depends on your viral load, hepatitis B status, kidney and bone health, other medications, and cost.

Is there a new once-daily HIV pill in 2026?

Yes. FDA approved Idvynso (doravirine/islatravir) on April 20, 2026 as a complete once-daily regimen for adults who are already virally suppressed on a stable regimen, with no history of treatment failure and no known doravirine resistance. It is a switch option, not a starting regimen.

Do I have to take my HIV pill with food?

It depends on the pill. Biktarvy and Dovato can be taken with or without food. Odefsey must be taken with a meal and cannot be combined with a proton pump inhibitor. Symtuza is taken with food. Ask your pharmacist about your specific tablet.

Is one pill always better than two?

Not automatically. The guidelines recommend single-tablet regimens when clinically appropriate but note that high-quality evidence to definitively recommend them is lacking, and that shared decision-making matters. As they put it, the only regimen that works is the one a person can obtain and is willing and able to take.

Treatment Hub
How modern HIV treatment works, from first prescription to lifelong suppression.
How long does it take to become undetectable?
What to expect in the first weeks and months on treatment.
Is undetectable really untransmittable?
The evidence behind U=U and the conditions it depends on.
I just tested positive — what do I do?
First steps, first appointments, and what actually happens next.
Policy & Advocacy
ADAP, Ryan White, and the Florida funding fights that shape access.
What HIV actually feels like, stage by stage, from a PLWH perspective.
HIV Testing Options
Window periods, test types, and where to test — including free Florida options.
Newly Diagnosed
The first 24 hours, first 7 days, first 30 days after a positive test.
HIV Symptoms in Women
How symptoms and progression can differ, and why women are diagnosed later.
Undetectable = Untransmittable
The clinical evidence behind U=U and what "undetectable" actually means.
Last reviewed: August 30, 2026 by the RiseUpToHIV. Educational content only — not medical advice.

References & Sources

  1. HHS/NIH — What to Start: Initial Combination Antiretroviral Regimens. First-line and situation-specific initial regimens, evidence ratings, food rules, and TAF vs TDF trade-offs. ↩ ↩ ↩ ↩ ↩
  2. HHS/NIH — What's New in the Adult and Adolescent Antiretroviral Guidelines. Guideline update dates, including the May 27, 2026 revision. ↩
  3. HHS/NIH — Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (full PDF). Adherence and regimen-selection sections, including the single-tablet BIII recommendation and resistance-barrier rankings. ↩ ↩ ↩ ↩
  4. NIH HIVinfo — FDA-Approved HIV Medicines. Brand names, components, and FDA approval dates for each single-tablet regimen. ↩
  5. FDA — Idvynso (doravirine/islatravir) approval letter, NDA 216964, April 20, 2026. Primary approval document and the exact indication wording for the 2026 addition. ↩ ↩
  6. NIH MedlinePlus — Bictegravir, Emtricitabine, and Tenofovir Alafenamide (Biktarvy). Patient-facing dosing and food information. ↩
  7. Florida Department of Health — ADAP Formulary, July 2026. Current list of antiretrovirals covered by Florida's AIDS Drug Assistance Program. ↩
  8. Florida Department of Health — AIDS Drug Assistance Program. Eligibility criteria, the July 1, 2026 Biktarvy restoration, and ADAP contact numbers. ↩ ↩
  9. WLRN — Intact but not in use: Florida's AIDS drug formulary advisory panel (April 8, 2026). Reporting on the March 1, 2026 Biktarvy removal, the projected shortfall, and the HB 697 restoration. ↩

Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.